, /PRNewswire/ -- Insmed Incorporated (Nasdaq: ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, , at to discuss topline results from the study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. The Company plans to issue a press release sharing the topline results at approximately , prior to the start of the conference call. Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.
S.) or (646) 307-1963 (international) and referencing access code 1245105. The call will also be webcast live on the Company's website at .
A replay of the conference call will be accessible approximately one hour after its completion through June 27, 2024, by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) and referencing access code 1245105.
A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at . Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease.
T.
